Business
Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease - Endpoints News
Reshma Kewalramani is putting Vertex's $10 billion-plus balance sheet to work. On Wednesday, the biotech announced it would pay $4.9 billion for Alpine Immune Sciences and its experimental drug povetacicept to treat IgA nephropathy, a kidney disease
By: Endpoints News
- Apr 12 2024
- 0
- 0 Views
ReshÂma KeÂwalÂraÂmani is putting VerÂtex’s $10 bilÂlion-plus balÂance sheet to work.
On WednesÂday, the biotech anÂnounced it would pay $4.9 bilÂlion for Alpine ImÂmune SciÂences and its exÂperÂiÂm… [+579 chars]